Inclusion Criteria

Celecoxib Study:

INCLUSION CRITERIA:

Recruitment will include patients with early onset of temporomandibular disorder, whose
primary diagnosis consists of anterior disc displacements with reduction as defined by the
Research Diagnostic Criteria (RDC).

Subjects are required to have preauricular pain for a minimum of one month, a primary TMD
diagnosis of TMJ disc displacement, and clinical and radiographic evidence of
disc-displacement.

EXCLUSION CRITERIA:

Subjects who had undergone any TMJ surgery within the preceding 6 months in any active way
will be excluded as will those who are taking regularly analgesic, anti-inflammatory,
steroids or narcotics medications.

Further exclusion criteria will be patients who have any TMJ growth disturbances.
Patients with red, hot, swollen, tendered TM joints, or those by medical history consist
of infectious arthritis, crystal induced arthropathies, and musculoskeletal disorders will
be excluded.

Patients will be screened for any positive history of liver or kidney dysfunctions.
Patients who have known hypersensitivity to celecoxib, are allergic to sulfonamides, or
have demonstrated allergic-type reactions after taking aspirin or other NSAIDs will be
excluded.

Subjects that have primary psychiatric disease or score above average or higher in
comparison with normative scores on Symptom Checklist (SCL-90R) will be able to
participate.

Subjects with any obvious occlusal disturbances such as cross-bite, open-bite, full
dentures will be disqualified.

Children under the age of 18 will be excluded from the study.

Pregnant women will not be included in the study.

Etanercept Study:

INCLUSION CRITERIA:

For the etanercept study, we will recruitment patients who are in the later stage of
temporomandibular disorder, who are not responding to standard non-surgical TMD therapy
(i.e., splints, physical therapy, biofeedback, trigger point injections), whose primary
diagnosis consists of TMJ osteoarthritis as defined by the Research Diagnostic Criteria.

Subjects are required to have preauricular pain for a minimum of three months with
clinical and radiographic evidence TMJ arthritis.

EXCLUSION CRITERIA:

Subjects who had undergone TMJ surgery within the preceding 6 months in any active way
will be excluded.

Subjects that are taking regularly steroids or narcotics medications will be excluded.

Further exclusion criteria will be presence of TMJ growth disturbances. Patients with
red, hot, swollen, tendered TM joints, TMJ infections or those with medical history
consist of infectious arthritis, crystal induced arthropathies, and musculoskeletal
disorders will be disqualified.

Patients with sepsis or with known hypersensitivity to etanercept or any of its components
will be excluded from the study.

Any patients with a medical history of diabetes, congestive heart failure, or any chronic
infections will be excluded.

Children under the age of 18 will not be included.

Pregnant women will not be included.